Atrial Fibrillation Progression Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 255 participants.

Also called NCT01570361

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 255 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01570361
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01570361. Randomized; no masking; primary purpose treatment. Start 2012-02-13 (actual); primary completion 2018-12-19 (actual). Results posted on 2020-05-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Atrial Fibrillation Progression Trial
Acronym
ATTEST
Intervention (Device)
Catheter Ablation
Intervention (Drug)
Drug Treatment
Lead sponsor
Biosense Webster, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01570361
Content hash
871683b78dfad9b78725233c06607e54fe0c604d7f4362fc554cf24c35e98ed6